Olalekan “Lekan” Ajayi, PharmD, MBA, is Chief Operating Officer for Highlands Oncology Group, P.A. In this role, Dr. Ajayi oversees the deployment of strategic initiatives into operational goals for all organizational service lines, including oncology. Dr. Ajayi currently serves on the Association of Community Cancer Centers (ACCC) Board of Trustees as the secretary.
Dr. Ajayi is passionate about leadership development and building high-performance teams through the application of operational excellence principles. He holds a Doctor of Pharmacy from the University of Wyoming and a Master of Business Administration from the University of Colorado Denver.
Devon Check, PhD, is a health services and implementation researcher. She is an assistant professor in the Department of Population Health Sciences at the Duke University School of Medicine and a member of the Duke Cancer Institute. Her primary research interests are quality of care and implementation of evidence-based practices in oncology. Dr. Check is particularly interested in symptom management and other aspects of supportive cancer care services. Her work combines quantitative and qualitative methods to understand and address barriers to the delivery of high-quality cancer care during and after treatment.
Dr. Check received her PhD in Health Policy and Management from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. Prior to joining the Department of Population Health Sciences at Duke, Dr. Check completed a postdoctoral fellowship in Delivery Science at Kaiser Permanente in northern California.
Amy Ellis is the chief quality officer at Northwest Medical Specialties (NWMS), who oversees its quality improvement, strategic practice initiatives, and value-based care programs, including the Oncology Care Model, Oncology Medical Home, and various commercial payment models. Amy works to continually transform the way care is provided to patients by utilizing innovative tools, such as artificial intelligence, care management technology, electronic patient-reported outcomes, population health technology, continual process improvement, and data analysis.
Amy brings 15 years of healthcare experience to the NWMS team, which includes clinical oncology research and alternative payment model implementation. Amy has been recognized for her work on the Payment Reform Committee with the Community Oncology Alliance, her active involvement in the Association of Community Cancer Centers’ committees and practice initiatives, as well as her value-based care leadership with the Quality Cancer Care Alliance Network and Washington state oncology initiatives. Amy is passionate about the quality of care provided to patients and strives to improve outcomes and the patient experience.
In 2019, Amy received a HemOnc Today’s Next Gen Innovator award for her forward-thinking approach in cancer care.
Douglas Flora, MD, LSSBB, serves as the executive medical director of Oncology Services at St. Elizabeth Cancer Center and was recently named the Robert and Dell Ann Sathe Endowed chair in Oncology. Dr. Flora is a board member of the Kentucky Society of Clinical Oncology, Andy & JJ Dalton Foundation, and American Cancer Society Area Board for Ohio, West Virginia, and Northern Kentucky.
He was born and raised in Cincinnati, Ohio, graduating from The Ohio State University College of Medicine in 1999. Dr. Flora has been named a Cincinnati Magazine “Top Doctor” in hematology and oncology for the past 15 years.
Douglas Flora, MD, LSSBB, serves as the Executive Medical Director of Oncology Services at St. Elizabeth Cancer Center and is a key player in developing a nationally recognized lung cancer screening program at St. Elizabeth Healthcare. Dr. Flora was named the Robert and Dell Ann Sathe Endowed Chair in Oncology. He serves on the Board of Directors for the American Cancer Society, the Association of Community Cancer Centers, and the Kentucky Society of Clinical Oncology.
Dr. Flora has a history of measurable success in managing all operations, including project management, policy development, staff engagement, budget planning, research, public education, and patient service. He applies Lean Six Sigma methodologies to improve patient experience and staff productivity. He is the Physician Leader instrumental in the development/launch of the Center for Precision Medicine & Genomic Health.
He was born and raised in Cincinnati, Ohio, graduating from The Ohio State University College of Medicine in 1999. Dr. Flora has been named a Cincinnati Magazine “Top Doctor” in hematology and oncology for consecutive years since 2005.
Sarah Hudson-DiSalle, PharmD, RPh, is the pharmacy manager at The Ohio State University Comprehensive Cancer Center – The James. She oversees and manages the medication assistance program and reimbursement services for infusion services. Dr. Hudson-DiSalle has a demonstrated history of working in the hospital and healthcare industry. She is skilled in healthcare information technology, hospitals, managed care, healthcare, revenue cycle management for pharmaceuticals, patient access to pharmaceuticals, and healthcare management.
Dr. Hudson-DiSalle earned a Bachelor of Science in pharmacy from the University of Toledo in 1995 and, after practicing pharmacy for seven years, earned her Doctor of Pharmacy from the The Ohio State University in 2005. She is passionate about her role in pharmacy, with a focus on patient access and reimbursement services for infusion medication at The James Cancer Hospital.
Edward S. Kim, MD, MBA, FACP, FASCO, is physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center. Dr. Kim joins City of Hope in fulfilling its promise of enhancing local access to cancer breakthroughs by leading its esteemed team of clinicians in Orange County, CA. Dr. Kim's goals for City of Hope are to promote strategic and team-oriented translational research and patient advocacy for greater accessibility and equitability in cancer care.
A U.S. News & World Report "Top Doctor" and clinician world-renowned for his immense oncology experience, Dr. Kim is poised to drive innovation in cancer care and delivery, developing paradigms for translating research into clinical practice and introducing new therapies for the Orange County clinical network and planned Irvine campus. Backed by a distinguished history of pioneering cancer research, Dr. Kim is among the country's foremost experts in molecular prognostication for lung cancer and head and neck cancers. He's served as a principal/co-principal investigator on numerous studies and protocols, and he has authored/co-authored more than 200 published articles, book chapters, and reviews in top-tier journals.
Before joining City of Hope, Dr. Kim was chair of Solid Tumor Oncology and Investigational Therapeutics, the Donald S. Kim Distinguished Chair for Cancer Research, medical director of the Clinical Trials Office at Levine Cancer Institute, and a professor of medicine at the University of North Carolina (UNC) at Chapel Hill. He has held many leadership roles, such as tenured associate professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Kim recently completed his MBA at the UNC Kenan-Flagler Business School.
Diane Portman, MD, FAAHPM, is an outpatient oncologic palliative medicine physician, writer, associate professor in Oncologic Sciences at the University of South& Florida, and chair of the Department of Supportive Care Medicine at Moffitt Cancer Center. Under Dr. Portman’s leadership, Moffitt has been recognized by The Joint Commission with advanced certification in palliative care, and the department was awarded the American Hospital Association’s 2018 Circle of Life Citation of Honor for its strides and innovations in palliative care.
Dr. Portman’s clinical practice focuses on whole-person therapy of cancer-related pain and other symptoms and supportive care communications. She teaches communications skills development workshops for oncology learners. Her research interests include symptom management and patient-reported outcomes, service delivery models, and quality assessment in palliative care, as well as communications in healthcare and the integration of palliative care in oncology services.
Nikoletta Sidiropoulos, MD, is an associate professor of Pathology and Laboratory Medicine at the University of Vermont (UVM) Larner College of Medicine, and she is the inaugural medical director of the Genomic Medicine Program at the UVM Medical Center. Dr. Sidiropoulos’ areas of expertise include molecular genetic pathology with subspecialty interests in oncology and quality improvement.
Dr. Sidiropoulos is a diplomate of the American Board of Pathology and American Board of Preventive Medicine in clinical informatics. She is also a member of the Roundtable on Genomics and Precision Health at The National Academies of Sciences, Engineering, and Medicine, and she is professionally involved with both the College of American Pathologists and Association for Molecular Pathology.
Dr. Sidiropoulos received her medical degree from the University of Connecticut School of Medicine, graduating with the award in “Excellence in Medical Studies.” She completed her residency in anatomic and clinical pathology at Dartmouth Hitchcock Medical Center and subsequently completed fellowships in cytopathology and molecular genetic pathology.